Home | All trials

[RDF data]
Trial NCT00000209

Resource URI: http://static.linkedct.org/resource/trials/NCT00000209
PropertyValue
linkedct:brief_title Buprenorphine Dosing Interval - 5
linkedct:condition <http://static.linkedct.org/resource/condition/9249>
linkedct:criteria Inclusion Criteria: M/F ages 21-50. Opiate dependence according to DSM-IV critera. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 50 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000209
rdfs:label Trial NCT00000209
linkedct:lastchanged_date August 16, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/209856>
linkedct:nct_id NCT00000209
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Buprenorphine Dosing Interval
linkedct:org_study_id NIDA-06082-5
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60742>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000209>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/14360>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/26212>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/7287>
linkedct:reference <http://static.linkedct.org/resource/reference/73>
linkedct:secondary_id R18-06082-5
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date November 1992
linkedct:study_design Treatment, Single Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
rdf:type linkedct:trials
linkedct:verification_date September 1994